Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | GPR6 | P46095 | 10/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467995 | 1.00 | DGAT2 (0.39) | DGAT2GPR6EGLN1PRKAA2IRAK4 | |
| SCHEMBL25837892 | 0.92 | USP30 (0.34) | DGAT2GPR6PRKAA2IRAK4 | |
| SCHEMBL30467966 | 0.92 | HDAC1 (0.38) | EGLN1 | |
| SCHEMBL30468009 | 0.92 | HDAC1 (0.38) | EGLN1 | |
| SCHEMBL30468018 | 0.92 | DGAT2 (0.37) | DGAT2GPR6PRKAA2 | |
| SCHEMBL30468036 | 0.92 | DGAT2 (0.37) | DGAT2GPR6PRKAA2 | |
| SCHEMBL30467952 | 0.90 | DGAT2 (0.38) | DGAT2GPR6EGLN1PRKAA2 | |
| SCHEMBL30468000 | 0.90 | DGAT2 (0.38) | DGAT2GPR6EGLN1PRKAA2 | |
| SCHEMBL24073558 | 0.90 | CETP (0.35) | GPR6IRAK4 | |
| SCHEMBL24073211 | 0.90 | CETP (0.35) | GPR6IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | claimed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | DGAT2 4734/4885GPR6 4140/4885EGLN1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.